đź’‰

Tirzepatide

Tirzepatide is a once-weekly injectable drug that produces the largest sustained weight loss of any medication currently approved, around 20% of body weight over 72 weeks at the top dose. It's sold as Zepbound for weight management and Mounjaro for type 2 diabetes. Both are the same molecule. Most people are here because they want significant fat loss, want to fix their blood sugar, or both, and lifestyle interventions alone haven't gotten them there.
It works by activating two gut hormone receptors (GLP-1 and GIP) that together kill appetite, slow digestion, and improve how your body handles glucose. The semaglutide one tier down (Ozempic, Wegovy) hits only GLP-1. Tirzepatide hits both, and the first head-to-head trial showed about 47% more weight loss than semaglutide at the maximum tolerated dose. The next tier up,
Retatrutide
Retatrutide
, adds a third receptor (glucagon) for even more weight loss but isn't approved yet.

Deep-dive

How it works. Tirzepatide is a single engineered peptide that binds two receptors your gut already uses to coordinate the response to a meal.
GLP-1 (glucagon-like peptide-1) is released by the gut after eating. It tells the brain you're full, slows the rate food leaves your stomach, and prompts the pancreas to release insulin. Slowed gastric emptying is the part you feel: meals sit longer, you stop being hungry between them, and the constant low-grade thinking about food fades.
GIP (glucose-dependent insulinotropic polypeptide) is released alongside GLP-1. It boosts the insulin response to a meal and appears to amplify the appetite-suppressing signal in the brain when paired with GLP-1. For years researchers thought GIP was either redundant or actively counterproductive. Tirzepatide overturned that. The dual mechanism produces more weight loss than maxing out GLP-1 alone, which is the main reason it outperforms semaglutide.
Half-life is around 5 days, which is why it's dosed once weekly.
The weight-loss data. SURMOUNT-1 was the primary obesity trial, 2,539 adults with obesity but without type 2 diabetes, 72 weeks. Average weight loss was 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg, versus 2.4% on placebo. About 91% of people on tirzepatide lost at least 5% of their body weight, and 63% on the top dose lost at least 20%. The 3-year follow-up showed weight loss was sustained and the rate of progression from prediabetes to type 2 diabetes was reduced by about 93% compared to placebo. This is one of the cleanest signals in modern metabolic medicine.
Versus semaglutide. SURMOUNT-5 was the first direct head-to-head, 751 adults with obesity randomised to maximum tolerated tirzepatide or semaglutide for 72 weeks. Tirzepatide produced 20.2% mean weight loss versus 13.7% on semaglutide, a 47% relative advantage. Waist circumference dropped 18.4 cm versus 13.0 cm. Tirzepatide had fewer GI discontinuations (2.7% vs 5.6%). A post-hoc analysis projected the predicted 10-year cardiovascular risk reduction was about 2.4% absolute on tirzepatide versus 1.4% on semaglutide. The two drugs feel different too: semaglutide skews toward nausea and constipation, tirzepatide more toward diarrhoea, with less nausea overall.
Diabetes outcomes. SURPASS-2 compared tirzepatide head-to-head against semaglutide 1 mg in people with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions, with the 15 mg dose bringing average A1c from 8.28% down to roughly 5.8%, essentially the non-diabetic range. Across SURPASS-1 through -5, the 15 mg dose reduced A1c by 2.0-2.6 percentage points and weight by 8-13 kg depending on the comparator. For type 2 diabetes, tirzepatide is currently the most effective non-insulin option.
Sleep apnoea. SURMOUNT-OSA was the first obesity drug trial in moderate-to-severe obstructive sleep apnoea. After 52 weeks, the apnoea-hypopnoea index dropped by roughly 25-30 events per hour on tirzepatide versus minimal change on placebo, in both CPAP-using and CPAP-naive participants. The FDA approved tirzepatide for OSA in December 2024, the first medication ever approved for the condition. If you snore heavily, wake up unrefreshed, and carry weight around the neck, this matters.
Liver. Roughly a third of adults have metabolic dysfunction-associated steatotic liver disease (MASLD, the new name for fatty liver). In the phase 2 SYNERGY-NASH trial, 52 weeks of tirzepatide resolved MASH without worsening fibrosis in a majority of treated participants. The dual GIP/GLP-1 mechanism plus the magnitude of weight loss appears to clear liver fat in a way diet alone rarely matches. EASL guidelines now recommend it for MASLD in patients with obesity, type 2 diabetes, or cardiometabolic risk.
Cardiovascular. Tirzepatide doesn't yet have a dedicated major cardiovascular outcomes trial (SURPASS-CVOT is ongoing). Real-world data from the Cleveland Clinic comparing tirzepatide and semaglutide in MASLD patients with diabetes found tirzepatide associated with lower major adverse cardiovascular events, all-cause mortality, and hospitalisations, though that's observational, not randomised. The cardiometabolic improvements (blood pressure, lipids, inflammation, waist) are consistent enough that the expected outcome trial result is favourable, but it isn't proven yet.
Women. Women make up about 70% of GLP-1 users and respond more strongly. A pooled SURMOUNT analysis of 4,677 participants found women lost more weight than men at every dose (-11.5% to -27.6% in women vs -8.8% to -18.9% in men), but also had a 2.5-fold higher rate of nausea and vomiting and were about 16% more likely to discontinue the drug. Women in the high-oestrogen phase of the cycle may notice appetite suppression more strongly (preclinical work suggests oestrogen amplifies GLP-1 signalling). The reproductive stage analysis found premenopausal and perimenopausal women hit nearly 20% weight loss, while postmenopausal women not on hormone therapy hit closer to 15%. A separate Mayo Clinic cohort found postmenopausal women on hormone therapy lost roughly the same 20% as younger women, suggesting oestrogen status modifies response. Significant weight loss can also temporarily disrupt menstrual cycles (typically settles within 3-6 months) and improves PCOS-related cycle irregularity in many users.
Body composition. In the SURMOUNT-1 DXA substudy, participants lost 21.3% of body weight, made up of 33.9% fat mass and 10.9% lean mass. Roughly 70-75% of the weight lost is fat, 25-30% is lean tissue. That ratio is typical for any significant weight loss method, not a specific tirzepatide effect, but it's the practical bottleneck. Without resistance training and adequate protein, lean mass loss is meaningful. With both, most of the weight that comes off is fat.
What it doesn't do as well. Tirzepatide doesn't meaningfully raise HDL. It doesn't seem to have the strong dedicated kidney outcomes data that semaglutide has from SELECT, so for diabetic kidney disease specifically, semaglutide currently has the better evidence base. And it doesn't fix the underlying physiology, when the drug stops, appetite usually returns and weight regain happens. SURMOUNT-4 showed about half the weight regained within a year of stopping. Plan to either run it long-term or use the window to build the habits that hold weight steady afterward.
Limits of the evidence. Most controlled data tops out at 3 years. Effects of stopping and restarting, exposure in early pregnancy, very long-term body composition and bone density, and any cancer signal beyond thyroid C-cell tumours in rodents are open questions. The drug has only been used at weight-loss doses widely since 2022. We're not in uncharted territory mechanism-wise (GLP-1 drugs have been around since 2005), but we are at the higher end of cumulative exposure.

Dosage

  • Schedule: Once-weekly subcutaneous injection into abdomen, thigh, or upper arm. Rotate sites. The full FDA dose ladder is 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with a minimum of 4 weeks at each dose before stepping up
  • Starting dose: 2.5 mg weekly for 4 weeks. This is a tolerance dose, not a therapeutic dose. Don't expect weight loss in this window. Its job is to let your gut adapt to slowed gastric emptying
  • Titration: Step up by 2.5 mg every 4 weeks as tolerated. If side effects at a step are significant, hold that dose for another 4 weeks before going up. Reaching 15 mg takes 21 weeks if you escalate every 4 weeks without holds
  • Maintenance: Approved maintenance doses are 5, 10, or 15 mg. You don't have to reach 15. Many people find their effective dose at 7.5 or 10 mg, where appetite is suppressed enough to drive sustained loss and side effects are manageable. Stop escalating once you're losing weight at an acceptable rate with tolerable side effects
  • Women generally do well starting at 2.5 mg and may need slower titration. Higher rate of nausea and vomiting means a 6-week hold at each step is reasonable if GI side effects don't settle
  • Older adults (60+) typically respond at lower doses. Starting at 2.5 mg and holding at 5 or 7.5 mg is often enough, since age-related GI sensitivity is real and the muscle preservation calculus matters more
  • Missed doses: Take within 4 days (96 hours) of the scheduled day. Beyond that, skip and resume the normal schedule. Always at least 72 hours between consecutive doses
  • Forms: Branded Zepbound (weight management) and Mounjaro (diabetes) are the same molecule in single-use pens. Compounded tirzepatide is widely sold via telehealth in vials at variable concentration and requires drawing with an insulin syringe. Quality varies. If you go compounded, source matters more than price
  • Stack with resistance training and protein. This is not optional. 1.6-2.0 g protein per kg of target body weight per day, plus 2-3 resistance sessions weekly. Without this, a meaningful share of what you lose is muscle. Consider also
    Creatine
    Creatine
    at 3-5 g daily for the muscle preservation effect
  • Don't stack with other GLP-1 drugs. You'll dose-stack the side effects without additional benefit

Here's what you can expect

Appetite suppression starts in the first 1-2 weeks at the 2.5 mg dose. The signal is unmistakable. You stop thinking about food between meals. Portions you used to finish feel like too much. Constant background hunger goes quiet. People describe this as the "food noise" turning off.
Weight on the scale moves slowly at first. The 2.5 mg starter dose isn't enough to drive significant loss for most people, that's expected. Loss accelerates as you titrate up. By 5-7.5 mg most people are losing 0.5-1% of body weight per week. By the time you reach maintenance the curve flattens but doesn't plateau for months.
Meals taste different. Greasy food and alcohol feel heavier and less appealing. Many people report wine and spirits hit harder on much less, because slowed gastric emptying changes how fast alcohol reaches the bloodstream. Cravings for sweet and processed food fade. Some people lose interest in food they used to love, which can read as a loss of pleasure.
Energy can dip in the first 4-8 weeks while your body adjusts to running on a calorie deficit you didn't choose consciously. This usually settles. If it doesn't, you're probably under-eating protein or undersleeping.
Women often notice cycle changes in the first few months. Lighter or skipped periods, shifted timing. This usually settles within 3-6 months as weight stabilises. Women with PCOS often see cycles regularise as insulin sensitivity improves.
Clothes start fitting differently before the scale shifts dramatically, especially around the waist. Waist circumference drops faster than total weight in the SURMOUNT trials, and visceral fat (around organs) drops disproportionately. This is the metabolically important kind to lose.
Facial fat thins. "Ozempic face" is real on tirzepatide too. The face has discrete fat pads that lose volume alongside the rest of the body, and the skin doesn't always retract at the same pace. Most apparent in people losing 15%+ of body weight, and more visible in people over 40.
If you stop, expect regain. Around 50% of lost weight comes back within a year of stopping if you do nothing else. The drug is doing the work, when it leaves, the appetite signals return. The window of weight loss is a chance to lock in habits (training, food environment, sleep) that hold the new weight afterward.

Side effects & risks

Gastrointestinal (very common, 40-50%). Nausea, diarrhoea, constipation, vomiting, bloating. Worst in the first 2-3 weeks after each dose increase, then settles. Manage by eating smaller portions, prioritising protein, hydrating aggressively, and reducing fatty and greasy meals. For constipation,
Magnesium
Magnesium
glycinate before bed and adequate fibre work better than laxatives. Nausea is worst the 24-48 hours after injection. Inject in the evening if you'd rather sleep through the worst of it. Women experience nausea and vomiting at roughly 2.5x the rate men do.
Muscle loss (common). Around 25-30% of the weight lost is lean mass without active intervention. Resistance training 2-3x weekly plus 1.6-2.0 g/kg protein daily roughly halves this. The drug doesn't directly cause muscle wasting, the calorie deficit and slowed appetite for protein-rich foods do. Track grip strength or a single lift like a goblet squat or deadlift over time as a proxy. If strength drops, eat more protein, lift more.
Hair loss. Telogen effluvium from rapid weight loss, not a direct drug effect. Diffuse shedding starting 2-4 months in, usually peaks at 6 months and regrows by 9-12 months. More common with faster, more aggressive loss. Adequate protein, iron, and zinc help.
Gallbladder disease (1-3%). Rapid weight loss mobilises stored fat into the liver, which oversaturates bile with cholesterol and increases gallstone risk. Not specific to tirzepatide, the same happens with bariatric surgery and very low-calorie diets. Symptoms: right upper abdomen pain after fatty meals, fever, jaundice. Persistent right upper quadrant pain warrants imaging.
Pancreatitis (rare, <0.2% in trials). Severe central abdominal pain radiating to the back, often with nausea and vomiting. Stop the drug and seek medical attention immediately. People with a history of pancreatitis should approach this drug cautiously.
Heart rate elevation (modest). Resting heart rate typically rises 2-5 bpm. Less than retatrutide because tirzepatide doesn't hit the glucagon receptor. If you're checking your wearable, you may notice slightly reduced HRV. This is mechanical, not a recovery problem.
Thyroid C-cell tumours. Found in rodents but not confirmed in humans across 20+ years of GLP-1 drug use. FDA boxed warning. Contraindicated if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
NAION (rare). Non-arteritic anterior ischaemic optic neuropathy, sudden vision loss in one eye, has been reported in association with GLP-1 drugs at low absolute rates. Mechanism unclear. Sudden vision changes warrant immediate evaluation.
Gastroparesis. Slowed gastric emptying is the desired mechanism, but in a small minority it persists past dose adjustments and becomes symptomatic (chronic nausea, early satiety, delayed digestion). Active litigation around this exists. Reversible in most cases after stopping the drug.
Mood flattening (anecdotal but consistent). Many users report a general flattening of motivation, pleasure, and interest in things they used to enjoy, food first but sometimes extending broader. Not depression in the clinical sense, more an overall dampening. Some literature suggests downstream dopamine effects from reduced palatable food intake. Usually settles or resolves on discontinuation.
Pregnancy. Stop tirzepatide at least 2 months before trying to conceive. The half-life is long and reproductive safety data is limited. Fertility often improves significantly with weight loss, which means accidental pregnancy in the first few months is more common than people expect, especially in women with PCOS who weren't getting regular ovulation.
Alcohol. Tolerance drops noticeably. Slowed gastric emptying means alcohol hits the small intestine more slowly, but the metabolic effects compound. Plan accordingly.
Long-term safety. Controlled data extends to about 3 years. We don't yet have 10+ year data at obesity-treatment doses. Class data on GLP-1 drugs at lower doses goes back to 2005 and is reassuring, but the specific question of decades at 10-15 mg tirzepatide isn't answered.

🩸

Blood markers

HbA1c, fasting glucose, fasting insulin at baseline. HOMA-IR (calculated from fasting glucose and insulin) tells you where your insulin resistance sits. Recheck at 3 and 6 months. If you're not diabetic going in but A1c is in the prediabetic range (5.7-6.4%), expect a meaningful drop.
Lipid panel (LDL, HDL, triglycerides, ApoB if available) at baseline. Triglycerides come down substantially with weight loss. LDL improves modestly. HDL doesn't move much, that responds to cardio and diet. Recheck at 3 and 6 months, then annually.
ALT and AST at baseline. ALT rises with liver fat. If you're carrying significant abdominal weight, ALT is often quietly elevated and tracks down as the liver clears. Recheck at 3 and 6 months.
Amylase and lipase at baseline given pancreatitis risk. Don't recheck routinely. Recheck only if you develop persistent upper abdominal pain.
Creatinine and eGFR at baseline. GLP-1 drugs have mild protective kidney effects but you want a reference point. Recheck at 6 months and annually.
TSH at baseline. Useful as a thyroid reference point given the boxed warning. Persistent neck lump, voice change, or trouble swallowing warrants direct imaging.
CBC including ferritin and B12 at baseline if you're a woman, vegetarian, or over 50. Rapid weight loss plus reduced appetite can drop iron and
Vitamin B12
Vitamin B12
stores, which compounds fatigue and hair loss. Recheck at 6 months.
DXA scan at baseline if you can access it. Lean mass loss is the main body-composition risk. Tracking with a scale alone hides whether you're losing fat or muscle. Recheck at 6 and 12 months. If lean mass is dropping faster than expected, increase protein and resistance training before adjusting the drug.
Blood pressure at baseline and monthly through titration. Usually drops with weight loss. If you're on antihypertensives, doses may need to come down to avoid lightheadedness.
Prescription only in the US, UK, EU, Australia, and most other jurisdictions. Compounded versions are widely available via telehealth where regulators permit it.